Drug companies are converging on India to conduct low-cost clinical trials. But is it ready to become the outsourcing centre for the world? T. V. Padma investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
T. V. Padma is a freelance writer based in New Delhi.
- T. V. Padma
Rights and permissions
About this article
Cite this article
Padma, T. India's drug tests. Nature 436, 485 (2005). https://doi.org/10.1038/436485a
Published:
Issue Date:
DOI: https://doi.org/10.1038/436485a
This article is cited by
-
A survey of South-North health biotech collaboration
Nature Biotechnology (2009)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.